cimadronate has been researched along with Kahler Disease in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hayakawa, H; Hayakawa, M; Miwa, A; Takezako, N; Tominaga, S; Yanagisawa, K | 1 |
| Iguchi, T; Ikeda, Y; Kizaki, M; Miyakawa, Y; Yamamoto, K | 1 |
| Ashihara, E; Fuchida, S; Hatsuse, M; Ochiai, N; Okamoto, M; Okano, A; Shimazaki, C; Uchida, R; Yamada, N | 1 |
| Ashihara, E; Fuchida, S; Inaba, T; Ochiai, N; Okamoto, M; Okano, A; Shimazaki, C; Uchida, R; Yamada, N | 1 |
| Akamatsu, S; Horiike, S; Inaba, T; Kanamura, N; Nomura, K; Okamoto, M; Shimazaki, C; Shimura, K; Taniguchi, K; Taniwaki, M; Uchida, R | 1 |
| Apperley, JF; Croucher, PI; Rogers, MJ; Russell, RG; Shipman, CM | 1 |
| Croucher, PI; Helfrich, MH; Rogers, MJ; Russell, RG; Shipman, CM | 1 |
| Ashihara, E; Hatsuse, M; Hirai, H; Inaba, T; Nakagawa, M; Okamoto, A; Okano, A; Shimazaki, C; Takahashi, R | 1 |
1 trial(s) available for cimadronate and Kahler Disease
| Article | Year |
|---|---|
Combination therapy with thalidomide, incadronate, and dexamethasone for relapsed or refractory multiple myeloma.
Topics: Aged; Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Dexamethasone; Diphosphonates; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Osteolysis; Recurrence; Thalidomide | 2005 |
7 other study(ies) available for cimadronate and Kahler Disease
| Article | Year |
|---|---|
YM-175 induces apoptosis of human native monocyte-lineage cells via inhibition of prenylation.
Topics: Apoptosis; Bone Density Conservation Agents; Cell Line, Tumor; Diphosphonates; Humans; Monocytes; Multiple Myeloma; Prenylation | 2012 |
Nitrogen-containing bisphosphonates induce S-phase cell cycle arrest and apoptosis of myeloma cells by activating MAPK pathway and inhibiting mevalonate pathway.
Topics: Apoptosis; Cell Division; Cell Line, Tumor; Checkpoint Kinase 1; Diphosphonates; Diterpenes; Enzyme Inhibitors; Farnesol; Humans; Imidazoles; Interleukin-6; MAP Kinase Signaling System; Mevalonic Acid; Multiple Myeloma; Phosphorylation; Protein Kinases; S Phase; Signal Transduction; Stromal Cells | 2003 |
Nitrogen-containing bisphosphonate incadronate augments the inhibitory effect of farnesyl transferase inhibitor tipifarnib on the growth of fresh and cloned myeloma cells in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Diphosphonates; Dose-Response Relationship, Drug; Drug Synergism; Farnesyltranstransferase; Humans; Multiple Myeloma; Quinolones; Tumor Cells, Cultured | 2005 |
Hyperbaric oxygen in addition to antibiotic therapy is effective for bisphosphonate-induced osteonecrosis of the jaw in a patient with multiple myeloma.
Topics: Anti-Bacterial Agents; Diagnostic Imaging; Diphosphonates; Humans; Hyperbaric Oxygenation; Jaw Diseases; Male; Mandible; Middle Aged; Multiple Myeloma; Osteonecrosis; Pain; Treatment Outcome | 2006 |
Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity.
Topics: Apoptosis; Clodronic Acid; Diphosphonates; DNA, Neoplasm; Humans; Multiple Myeloma; Pamidronate; Tumor Cells, Cultured | 1997 |
The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Division; Diphosphonates; Diterpenes; Enzyme Inhibitors; Farnesol; Humans; Lovastatin; Mevalonic Acid; Multiple Myeloma; Protein Prenylation; Tumor Cells, Cultured | 1998 |
A newly developed bisphosphonate, YM529, is a potent apoptosis inducer of human myeloma cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Division; Diphosphonates; Flow Cytometry; Humans; Imidazoles; Multiple Myeloma; Pamidronate; Tumor Cells, Cultured | 2001 |